NAD+:
The Master Molecule of Aging

Nicotinamide Adenine Dinucleotide — NAD+ — is a coenzyme found in every living cell on earth. It is not a single-purpose molecule. It does not do one thing and do it well. It is the central metabolic currency of the cell, required for hundreds of enzymatic reactions, present in two interconverting forms (NAD+ and NADH), and so fundamental to life that organisms from yeast to mammals have conserved it across billions of years of evolution. When researchers at the Sinclair Lab at Harvard and the de Cabo Lab at the NIH identified NAD+ decline as a primary driver of mammalian aging, it was not a fringe theory — it was the convergence of decades of research in metabolism, epigenetics, and DNA biology pointing at the same molecule.

In your twenties, your cells maintain robust NAD+ levels. The mitochondria hum with activity, producing ATP efficiently. SIRT1 and its sibling sirtuins patrol the genome, silencing inflammatory genes and activating repair. PARP enzymes fix DNA strand breaks as fast as they appear. The circadian clock ticks with clean amplitude, ensuring the cellular maintenance work of sleep runs on schedule. The system works because NAD+ is abundant.

By your forties and fifties, NAD+ levels have fallen by more than 50% relative to peak levels. This is not a minor perturbation — it is a systematic collapse of the molecule that powers the entire anti-aging apparatus. The decline is not caused by a single mechanism but by at least three converging processes that accelerate with age.

The first is PARP overconsumption. As we age, the rate of DNA damage increases — UV radiation, oxidative stress, environmental toxins, and metabolic byproducts all accumulate. PARP enzymes respond to every strand break by consuming NAD+ to build repair scaffolding. The more damage, the more PARP activity, the more NAD+ consumed. This creates a self-reinforcing downward spiral: NAD+ depletion reduces repair efficiency, which allows damage to accumulate faster, which activates more PARPs, which depletes NAD+ further.

The second is CD38 upregulation. CD38 is an enzyme that degrades NAD+ — and its expression increases dramatically with age and with chronic inflammation. Studies in mice show that CD38 knockout animals maintain significantly higher NAD+ levels into old age. In humans, elevated CD38 activity driven by senescent cells and inflammatory cytokines is a major accelerant of age-related NAD+ decline that is entirely independent of biosynthesis capacity.

The third is reduced biosynthesis. The salvage pathway — the primary route by which cells recycle NAD+ from breakdown products — becomes less efficient with age. NAMPT (Nicotinamide Phosphoribosyltransferase), the rate-limiting enzyme in this pathway, declines in expression and activity in multiple tissues. The result is that even if consumption were constant, production capacity falls short. With consumption simultaneously increasing, the gap between supply and demand widens with every passing year.

The consequence of this triple-mechanism collapse is that by middle age, your cells are attempting to run every energy, repair, and regulatory process on half the molecular fuel they once had. This is not a metaphor. It is a measurable biochemical reality — and it is addressable.

To understand why restoring NAD+ has such broad and profound effects, you need to understand the scope of what it does. NAD+ is not a supplement that supports one pathway. It is the substrate for four of the most fundamental biological processes involved in aging, energy, and health.

Because NAD+ underpins so many fundamental processes, its deficiency does not present as a single discrete symptom — it presents as a broad deterioration of multiple systems simultaneously. The clinical picture of NAD+ decline is recognizable precisely because it matches what we commonly attribute to "just getting older." That attribution, while understandable, obscures a mechanistically actionable cause.

NAD+ can be delivered through three primary routes: intravenous infusion, subcutaneous injection, and oral supplementation (as direct NAD+ or as precursors NMN/NR). Each has a distinct pharmacokinetic profile, and the optimal choice depends on your goals, access, and whether you are in a loading or maintenance phase.

IV infusion is the gold standard for acute NAD+ restoration. It delivers the highest plasma concentration, achieves cellular saturation fastest, and produces the most immediate symptomatic response — many users report the energy and clarity lift beginning within 30–60 minutes of starting an infusion. IV protocols are used by longevity clinics as loading phases before transitioning patients to self-administered SubQ maintenance. The flush sensation — warmth and tingling, most intense in the chest, face, and extremities — is universally reported and universally harmless. It results from NAD+-driven signaling cascades activating in high-metabolic-demand tissues and can be controlled by adjusting infusion rate.

Subcutaneous injection is the practical backbone of ongoing NAD+ protocols. It bypasses the digestive system entirely (unlike oral NMN/NR), delivers NAD+ directly into tissue, and achieves systemic levels that oral supplementation cannot reliably match — particularly in older individuals with reduced conversion enzyme activity. Daily SubQ dosing of 50–100mg is the standard maintenance protocol following an IV loading phase.

The case for direct NAD+ over NMN and NR is straightforward: precursors require enzymatic conversion steps — NMN to NAD+ requires NMNAT enzymes; NR to NAD+ requires both NRK and NMNAT. These conversion enzymes decline with age and vary between individuals. Direct NAD+ supplementation eliminates this variability and ensures the molecule your cells actually use is what reaches them.